Investigating ImmunityBio: The Fallout from Misleading Cancer Claims and Market Impact

ImmunityBio Under Fire for Misleading Claims

ImmunityBio, Inc. (NASDAQ: IBRX) is now at the center of a significant legal controversy following a securities class action lawsuit filed against it. The litigation aims to represent investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026. The legal action was precipitated by a stern warning from the FDA, which criticized the company for misleading claims made by its executive leadership regarding its flagship product, Anktiva.

Background of the Case

The saga began when Dr. Patrick Soon-Shiong, ImmunityBio's executive chairman and Chief Scientific and Medical Officer, made bold assertions during a direct-to-consumer podcast aired on January 19, 2026. Despite Anktiva being FDA-approved solely for the treatment of non-muscle invasive bladder cancer (NMIBC), Soon-Shiong controversially claimed it could be effective for treating "all cancers." This sweeping statement, along with other efficacy claims, was flagged by the FDA as misleading and unfounded.

By March 24, 2026, the fallout became evident as the FDA issued a warning letter to ImmunityBio, stating that the promotional materials from the podcast and a subsequent television ad were deceptive. The FDA's assessment indicated that these communications created the misleading impression that Anktiva could cure all types of cancer, significantly diverging from the actual approved use of the drug. Furthermore, they highlighted that the representations suggested that all patients treated with Anktiva would achieve long-term cancer-free status—a claim not backed by scientific evidence.

Market Impact

The repercussions of the FDA's warning were swift and severe. On the same day the news broke, ImmunityBio's stock price plummeted by over 21%, effectively erasing close to $2 billion from its market capitalization. Investors who had acquired shares during the affected period are now facing substantial financial losses. As a response to this critical situation, Hagens Berman, a prominent national shareholders rights law firm, launched an investigation into ImmunityBio's compliance with federal securities laws, aiming to uncover if the company knowingly misled its investors.

Legal Implications

This class action lawsuit brings to light several significant legal implications regarding investor protections and corporate transparency within the biotech sector. The claims focus primarily on whether ImmunityBio violated securities laws through the dissemination of misleading promotional content, and it signifies a growing concern among investors about corporate accountability in the healthcare space.

What Investors Should Know

For investors affected by this legal turmoil, especially those who witnessed steep losses in their ImmunityBio investments, Hagens Berman is encouraging individuals to come forward with information regarding their losses. Additionally, the firm is advocacy-based, seeking not only to recover losses on behalf of investors but also to hold ImmunityBio accountable for its actions.

Moreover, individuals with non-public information relevant to this case are urged to consider the SEC Whistleblower Program, which can offer rewards for information leading to successful enforcement actions. The stakes are high, and the outcomes of the investigations and subsequent legal actions could reshape both investor trust and regulatory scrutiny in the biotechnology industry.

Conclusion

As the case continues to unfold, all eyes will be on how ImmunityBio navigates this legal storm and whether it can restore its credibility and market standing. Investors are advised to stay informed about the developments through reputable channels and seek professional advice if they are considering their options moving forward.

In this volatile environment, the urgency for transparency and adherence to ethical marketing practices has never been clearer. Both the legal proceedings against ImmunityBio and the ongoing investigations will likely set important precedents for the biotech sector and the broader financial markets.